Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Single-Arm Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Serplulimab for Patients With Extensive-Stage Small Cell Lung Cancer

NCT05765825 is registered in ClinicalTrials.gov with Sichuan University as lead sponsor.

NCT NCT05765825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05765825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Single-Arm Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Serplulimab for Patients With Extensive-Stage Small Cell Lung Cancer
Lead sponsor
Sichuan University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 7, 2023
Completion date
December 31, 2026
Enrollment
61 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small-cell lung cancer